Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen

Opinion
Video

Noa Biran, MD, discusses how the phase III BOSTON trial evaluates selinexor + bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed/refractory myeloma.

Recent Videos
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
9 Experts are featured in this series.
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content
Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.

Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Russ Conroy
March 4th 2024
Article

Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.